Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp (NASDAQ:NVDA) has fully exited its investment in the AI‑focused drug‑discovery company. Here’s what you should know.
- Recursion Pharmaceuticals stock is showing weakness. What’s driving RXRX stock lower?
Nvidia Unwinds Multiple AI‑Focused Stakes
Nvidia revealed in a Tuesday filing that it no longer holds any Recursion shares as of Dec. 31, alongside similar exits from Applied Digital Corp (NASDAQ:APLD) and autonomous‑driving firm WeRide Inc (NASDAQ:WRD), Barron’s reported.
Nvidia’s positions in these companies were relatively small at the end of the third quarter of 2025, but the chipmaker has spent recent years building a portfolio of AI‑related investments across multiple industries.
Technical Indicators Point To Sustained Weakness
Recursion Pharmaceuticals is currently positioned below all key moving averages, indicating bearish momentum. The stock is trading 18.2% below its 20-day SMA, 22.5% below its 50-day SMA and significantly below its longer-term averages, suggesting a lack of upward strength.
The RSI is currently at 33.28, which is considered neutral but close to oversold territory, suggesting there could be potential for a bounce if buying interest picks up, but it also indicates that sellers have been in control. MACD is below its signal line, indicating bearish pressure on Recursion. The downward trend may continue unless we see a shift in momentum.
Over the past 12 months, Recursion Pharmaceuticals has seen a steep decline of 68.19%. This significant drop highlights the ongoing challenges the stock faces and the need for traders to remain cautious.
RXRX Price Action: Recursion shares were down 1.73% at $3.39 at the time of publication on Wednesday. The stock hit a new 52-week low on Wednesday before recovering some of its losses, according to Benzinga Pro.
Image: Shutterstock
Recent Comments